Spero Therapeutics (SPRO) Stock
Clinical stage drug developer for infectious diseases. Here's the price, business snapshot, and what's worth knowing about Spero Therapeutics in July 2026.
Spero Therapeutics Inc (SPRO) is a clinical‑stage biopharmaceutical company focusing on developing therapies for serious infectious diseases and other unmet medical needs. With a market capitalisation of about $133.37 million, SPRO is a small‑cap, higher‑risk stock where valuation tends to hinge on clinical trial results, regulatory milestones and partnerships or licensing deals. Investors should note the often binary nature of biotech development: clear positive data or approvals can materially change prospects, while setbacks can reduce value quickly. The company may currently have limited product revenue and rely on financing, collaborations or milestone payments to fund operations, which can dilute existing shareholders. Key evaluation points include pipeline stage, trial timelines, cash runway and partner exposure. This is general educational information only and not personalised investment advice. Biotech investing carries significant volatility and the potential for capital loss; consider your own objectives and seek independent financial advice if needed.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding SPERO Therapeutics' stock with a target price of $7.5, indicating possible growth.
Financial Health
Spero Therapeutics is earning reasonable revenue and cash flow, but financial stability needs improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring SPRO
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: 11 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage focus
Pipeline milestones and trial readouts often drive valuation; positive results can boost prospects, though outcomes are binary and share prices can move sharply.
Antibiotic innovation
Work on novel anti‑infectives may address unmet needs and attract partners, but scientific, regulatory and commercial hurdles remain.
Funding and runway
As a small‑cap, financing events and partnerships commonly fund operations; monitoring cash runway is important since funding can dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
